🔴 Tscan Therapeutics is trading 5.5% down today as recent gains from its TSC-101 program moderate amid sector-wide pressure

Tscan Therapeutics is trading 5.5% down today at $1.03 as recent gains from its TSC-101 program and FDA-aligned phase III plans begin to moderate.

• The pullback follows a sharp multi-day swing driven by positive updates on the ALLOHA trial and progress in clinical development.
• Broader market conditions are contributing to the decline, with high-beta biotech stocks facing pressure alongside a sector-wide pullback in the XBI.